Characteristics of included trials
| Study | Year | Study design | Treatment groups | No of patients | Age (years) | LDL-cholesterol (mg/dl) | Diabetes | Aortic jet velocity (m/sec) | Aortic valve area (cm2) | Transaortic pressure gradient (mm Hg) | Follow-up |
| Chan (ASTRONOMER)6 | 2010 | Prospective randomised | Placebo | 135 | 58±14 | 122±29 | NA | 3.19±0.42 | 1.56±0.70 | Mean 23±8 | Median 3.5 |
| Rosuvastatin 40 mg/day | 134 | 58±13 | 124±25 | NA | 3.16±0.42 | 1.49±0.71 | Mean 23±8 | (2.1–4.5) years | |||
| Cowell (SALTIRE)4 | 2005 | Prospective randomised | Placebo | 78 | 68±10 | 133±30 | 4 (5%) | 3.45±0.67 | 1.02±0.41 | Peak 50±20 | Median 25 |
| Atorvastatin 80 mg/day | 77 | 68±10 | 137±34 | 3 (4%) | 3.39±0.62 | 1.03±0.40 | Peak 48±17 | (7–36) months | |||
| Mohler 10 | 2007 | Prospective observational | No statins | 22 | 64±10 | 110±33 | 3 (14%) | NA | 1.22±0.25 | NA | 12 months |
| Statins | 31 | 70±10 | 7 (18%) | NA | 1.13±0.27 | NA | |||||
| Moura (RAAVE)11 | 2007 | Prospective open label | No treatment | 60 | 74±9 | 117±21 | 13 (22%) | 3.62±0.61 | 1.20±0.35 | Mean 36±13 | Mean 73±24 weeks |
| Rosuvastatin 20 mg/day | 61 | 73±9 | 158±32 | 26 (43%) | 3.65±0.64 | 1.23±0.43 | Mean 35±13 | ||||
| Rossebo (SEAS)5 | 2008 | Prospective randomised | Placebo | 929 | 67±10 | 139±35 | NA | 3.10±0.54 | 1.27±0.46 | Mean 23.0±8.7 | Median 52.2 months |
| Simvastatin (40–80 mg/day) plus ezetimibe | 944 | 68±9 | 140±36 | NA | 3.09±0.55 | 1.29±0.48 | Mean 22.7±8.8 | ||||
| Antonini-Canterin12 | 2008 | Retrospective | No statins mild aortic stenosis | 360 | 71±8 | NA | 82 (23%) | 2.3±0.2 | NA | Mean 13.1±3.2 | Mean 5.6±3.2 years |
| Statins mild aortic stenosis | 141 | 71±7 | NA | 50 (36%) | 2.3±0.2 | NA | Mean 12.7±3.1 | ||||
| No statins moderate aortic stenosis | 214 | 72±8 | NA | 42 (20%) | 3.3±0.2 | NA | Mean 26.1±5.1 | ||||
| Statins moderate aortic stenosis | 62 | 70±8 | NA | 14 (23%) | 3.3±0.2 | NA | Mean 26.0±5.0 | ||||
| Bellamy13 | 2002 | Retrospective | No statins | 118 | 78±12 | 137±43 | 28 (24%) | 3.0±0.8 | 1.20±0.35 | Mean 22±12 | Mean 3.7±2.3 years |
| Statins | 38 | 73±11 | 164±49 | 9 (24%) | 2.8±0.5 | 1.32±0.29 | Mean 18±7 | ||||
| Kuwabara14 | 2006 | Retrospective | No statins | 20 | 75±5 | NA | 3 (15%) | 3.1±1.0 | NA | Mean 42±29 | 31±23 months |
| Statins | 13 | 74±5 | NA | 6 (46%) | NA | 30±20 months | |||||
| Novaro15 | 2001 | Retrospective | No statins | 117 | 67±13 | 131 (112–143) | 23 (20%) | NA | 1.2 (1.0–1.4) | Mean 15 (12–22) | Mean 21 months |
| Statins | 57 | 71±9 | 128 (94–146) | 20 (35%) | NA | 1.2 (1.0–1.4) | Mean 15 (12–22) | ||||
| Rosenhek16 | 2004 | Retrospective | No statins | 161 | 69±11 | 141±39 | 32 (20%) | 3.92±0.86 | 0.84±0.23 | Mean 42±20 | Median 24±18 months |
| Statins | 50 | 72±8 | 145±38 | 11 (22%) | 4.08±0.86 | 0.82±0.23 | Mean 42±18 |
LDL, low-density lipoprotein.